University of Pennsylvania: Breast Neoplasms trials
The registry lists 18 Breast Neoplasms studies with University of Pennsylvania as lead sponsor. 1 are open to participants now and 1 have results posted.
Phase 1 6Phase 2 3No phase 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- B.Brilliant Revelation Comparision StudyRecruitingNCT07067788
- Clinical Utility Study of a Low-Cost Hand-Held Breast ScannerCompletedNCT02597452Not applicableResults posted
- CAR T Cells in Mesothelin-Expressing Breast CancerTerminatedNCT05623488Phase 1
- Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CTActive, not recruitingNCT03846167
- Abbreviated Breast MRI After Cancer TreatmentCompletedNCT03664778
- Oncology Episode Payment Model in HawaiiActive, not recruitingNCT03523546Not applicable
- [18F]FLT PET/CT in Rb+ Metastatic Breast CancerActive, not recruitingNCT02608216Phase 1
- [18F]FES PET/CT in Endocrine Refractory Breast CancerTerminatedNCT02409316Phase 2
- [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast CancerActive, not recruitingNCT02284919Phase 1
- Intraoperative Imagery of Breast Cancer With Folate-FITC (EC17)CompletedNCT01994369Phase 1
- PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer RiskCompletedNCT01879189Not applicable
- cMet CAR RNA T Cells Targeting Breast CancerCompletedNCT01837602Phase 1
- Breast Cancer Prevention EducationCompletedNCT01299623Not applicable
- Multipeptide Vaccine for Advanced Breast CancerCompletedNCT00573495Phase 1
- Genetic Counseling in African American WomenCompletedNCT00419510Not applicable
- Using Diagnostic Tools to Stage Breast CancerActive, not recruitingNCT00367666Not applicable
- Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted TherapyWithdrawnNCT00343759Phase 2
- Tamoxifen-MRI StudyCompletedNCT00295100Phase 2